比较 HER2 状态的视觉评估和自动评估及其对原发性可手术浸润性导管乳腺癌结局的影响。

Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer.

机构信息

Academic Unit of Surgery, College of Medical, Veterinary and Life Sciences, University of Glasgow, Royal InfirmaryUniversity Department of PathologyUnit of Experimental Therapeutics, Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Royal and Western InfirmaryDepartment of Surgery, Western Infirmary, Glasgow, UK.

出版信息

Histopathology. 2012 Oct;61(4):675-84. doi: 10.1111/j.1365-2559.2012.04280.x.

DOI:10.1111/j.1365-2559.2012.04280.x

PMID:22747525

Abstract

AIMS

To compare visual and computerized image analysis of HER2 immunohistochemistry (IHC) with fluorescence in-situ hybridization (FISH) for HER2 status, and to examine the relationships with outcome in patients with primary operable invasive ductal breast cancer.

METHODS AND RESULTS

Tissue microarrays for 431 breast cancer patients were used to compare different approaches to the assessment of HER2 status. The cores were scored visually and with the Slidepath Tissue IA system, using the NICE-approved scoring system for the HercepTest, as well as by FISH. The agreement between visual and image analysis of HER2 IHC was excellent [interclass correlation coefficient (ICCC) = 0.95, rs = 0.90, r = 0.91, k = 0.81, and P < 0.001]. The agreement of HER2 FISH with visual and image analysis of HER2 IHC was also excellent (ICCC = 0.95 and ICCC = 0.92, respectively). Univariate survival analysis showed equivalent associations of visual and image analysis of HER2 and HER2 FISH with both recurrence-free survival (all P < 0.01) and cancer-specific survival (all P < 0.05) in patients with invasive ductal breast cancer.

CONCLUSION

Computerized image analysis of HER2 IHC gives results comparable to those obtained with visual assessment, with possible advantages in diagnostic pathology.

摘要

目的

比较 HER2 免疫组织化学（IHC）的视觉和计算机图像分析与荧光原位杂交（FISH）在 HER2 状态检测中的结果，并研究其与原发性可手术浸润性导管乳腺癌患者预后的关系。

方法和结果

使用 431 例乳腺癌患者的组织微阵列来比较评估 HER2 状态的不同方法。采用 NICE 批准的 HercepTest 评分系统，通过视觉和 Slidepath Tissue IA 系统对核心进行评分，并进行 FISH 检测。HER2 IHC 视觉和图像分析之间的一致性非常好[组内相关系数（ICCC）=0.95，rs=0.90，r=0.91，k=0.81，P<0.001]。HER2 FISH 与 HER2 IHC 视觉和图像分析之间的一致性也非常好（ICCC=0.95 和 ICCC=0.92）。单因素生存分析显示，视觉和图像分析的 HER2 和 HER2 FISH 与浸润性导管乳腺癌患者的无复发生存（均 P<0.01）和癌症特异性生存（均 P<0.05）具有等效的相关性。